Abstract 5872: Investigation on the prevalence of germline and somatic mutations in gynecological malignancies: Implications for risk assessment and therapeutic decision-making
Hao Wen(Fudan University Shanghai Cancer Center), Xiaohua Wu(Fudan University Shanghai Cancer Center), Huawen Li(Jinan University), Qin Xu(Anhui Medical University), Xipeng Wang(Shanghai Jiao Tong University), Xiujie Sheng(Third Affiliated Hospital of Guangzhou Medical University)
Cited by 0
Related Papers
Durvalumab versus placebo with chemoradiotherapy for locally advanced cervical cancer (CALLA): a randomised, double-blind, phase 3 trial
|The Lancet Oncology|2023|214
Treatment With Niraparib Maintenance Therapy in Patients With Newly Diagnosed Advanced Ovarian Cancer
|JAMA Oncology|2023|165
Ovarian Cancer-Intrinsic Fatty Acid Synthase Prevents Anti-tumor Immunity by Disrupting Tumor-Infiltrating Dendritic Cells
|Frontiers in Immunology|2018|156
Integration of immunotherapy into treatment of cervical cancer: Recent data and ongoing trials
|Cancer Treatment Reviews|2022|135
Immunogenic Cell Death-Based Cancer Vaccines
|Frontiers in Immunology|2021|95